Danish Software Stock News

Recent performance snapshot A.P. Møller - Mærsk (CPSE:MAERSK B) has seen mixed short term returns, with a gain of about 1.1% over the past day, a 5.5% decline over the past week, and a 2.9% rise over the past month. Looking a bit further back, the stock shows a 15.4% return over the past 3 months and around 0.6% year to date. The 1 year total return stands at about 56.0%. See our latest analysis for A.P. Møller - Mærsk. At a share price of DKK 14,860, A.P. Møller - Mærsk combines a recent dip...

Tryg (CPH:TRYG) has had a rough month with its share price down 1.6%. However, the company's fundamentals look pretty...

One thing we could say about the covering analyst on cBrain A/S ( CPH:CBRAIN ) - they aren't optimistic, having just...

Novo Nordisk (CPSE:NOVO B) expanded its partnership with Aspect Biosystems to develop next generation cell based diabetes therapies. The company launched an oral formulation of Wegovy, with early signs of strong market uptake in the weight loss segment. A federal antitrust lawsuit was filed alleging Novo Nordisk used its position in GLP 1 medicines to limit compounding pharmacy competition. Novo Nordisk, traded as CPSE:NOVO B, is active in both diabetes care and prescription weight loss...

RIAS A/S ( CPH:RIAS B ) has announced that on 26th of January, it will be paying a dividend ofDKK26.00, which a...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

To the annoyance of some shareholders, Pandora A/S ( CPH:PNDORA ) shares are down a considerable 26% in the last month...

What Novo Nordisk’s recent performance data tells you Novo Nordisk (CPSE:NOVO B) has seen mixed share performance recently, with about a 3% decline over 1 day, a broadly flat past week, and gains over the past month and past 3 months. See our latest analysis for Novo Nordisk. At a share price of DKK 377.55, Novo Nordisk’s recent 21.79% 1 month share price return contrasts with a weaker 1 year total shareholder return of 29.56% and a stronger 5 year total shareholder return of 83.01%. This...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Amylyx Pharmaceuticals recently selected AMX0318, a long-acting GLP-1 receptor antagonist discovered in collaboration with Gubra, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a US$4,000,000 milestone payment and positioning Gubra for more than US$50,000,000 in potential future milestones plus mid-single digit royalties. The move underlines how Gubra’s partnered peptide programs can translate preclinical research into tangible milestone income...

Ambu A/S recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting its single-use endoscopy focus and turnaround progress. The company used the conference platform to showcase innovation, scalable operations, and an improved financial outlook that could influence how investors view its recovery narrative. Next, we examine how Ambu’s emphasis on single-use endoscopy leadership and turnaround progress at the conference shapes its investment...

Hove A/S ( CPH:HOVE ) shares have continued their recent momentum with a 27% gain in the last month alone. The annual...

Brd. Klee A/S ( CPH:KLEE B ) is about to trade ex-dividend in the next three days. The ex-dividend date generally...

Genmab A/S recently reported topline Phase 3 EPCORE DLBCL-1 data showing that subcutaneous epcoritamab monotherapy improved progression-free survival versus standard chemo‑immunotherapy in previously treated, transplant‑ineligible diffuse large B‑cell lymphoma patients, with safety consistent with its known profile. This is the first Phase 3 trial to show a progression-free survival benefit for a CD3xCD20 bispecific antibody used as monotherapy in relapsed or refractory diffuse large B‑cell...

It's shaping up to be a tough period for Bang & Olufsen A/S ( CPH:BO ), which a week ago released some disappointing...

Novo Nordisk A/S ( CPH:NOVO B ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

Why the Revolution Wind ruling matters for Ørsted A US federal judge has allowed Ørsted (CPSE:ORSTED) to restart construction on its nearly finished, roughly US$5.0b Revolution Wind project, removing the prior national security suspension and shifting attention back to project delivery and capital returns. See our latest analysis for Ørsted. Against this legal win, Ørsted’s share price has a 1 day return of 3.4% and a 90 day share price return of 13.15%. However, the 1 year total shareholder...

TORM plc recently announced that Oaktree Capital Management’s ownership has fallen below the one-third threshold, triggering the extinguishing of the B-Director role, the departure of Deputy Chairman and Senior Independent Director David Weinstein from the Board as of 6 January 2026, and the planned redemption and cancellation of the company’s B- and C-shares. These governance changes remove special voting arrangements, consolidating power into a single class of 101,332,707 A-shares and one...

Pandora A/S recently held its Q4 2025 guidance/update call, confirming expectations for 2025 including EBIT of around DKK 7.8 billion and a group EBIT margin of roughly 24% supported by strong gross margin and cost control. This confirmation of robust profitability targets and disciplined cost management offers fresh insight into how Pandora sees its operational efficiency holding up through 2025. Next, we’ll examine how Pandora’s expectation of an EBIT margin around 24% might influence the...

If you are trying to figure out whether A.P. Møller - Mærsk shares still offer good value, it helps to separate the story from the numbers and look at what the current price actually reflects. The stock recently closed at DKK 14,900, with returns of 1.4% year to date and 58.0% over the past year, which can change how the market sees both its growth potential and risk. Recent headlines around global shipping capacity, freight rate volatility, and trade route disruptions have kept container...

On 2 January 2026, Schouw & Co. began a share buy-back programme of up to DKK 240,000,000 running through 31 December 2026 under EU Safe Harbour rules. This substantial capital allocation move signals management’s focus on returning cash to shareholders while potentially tightening the company’s free float over time. We’ll now examine how this sizeable buy-back programme could influence Schouw’s investment narrative, especially around capital allocation and earnings quality. Find companies...

Rockwool (CPSE:ROCK B) is back in focus after Russian authorities assumed control of its four factories in the country. This has prompted the company to deconsolidate these assets and prepare to defend its rights under international treaties. See our latest analysis for Rockwool. At a share price of DKK 211.0, Rockwool has a 7 day share price return of 6.16% and a 30 day share price return of 7.70%, while the 1 year total shareholder return of 13.78% contrasts with a 3 year total shareholder...

In recent days, analysts at Bernstein and Goldman Sachs have highlighted DSV as a preferred name in European logistics, emphasizing its asset-light model, Schenker integration capabilities, and potential capital markets day and share buyback catalysts in 2026, while the company also exited USA Truck and managed a warehouse fire in Poland. This combination of renewed analyst attention, portfolio reshaping through the USA Truck sale, and operational incident management is shaping how investors...

ISS share buyback puts capital return in focus ISS (CPSE:ISS) recently announced a new share buyback programme aimed at returning excess cash to shareholders by reducing share capital and meeting obligations under its share based incentive schemes. Management is executing the programme under Market Abuse Regulation and the Safe Harbour Regulation, with ISS now holding 13,125,562 treasury shares, equal to 7.53% of the company’s total share capital. See our latest analysis for ISS. The buyback...